Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

he Aloxi package insert, available at www.mgipharma.com and www.aloxi.com, for important additional details.

About Dacogen(R) For Injection

Dacogen is approved by the U.S Food and Drug Administration for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups. Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for 2 months afterwards. In clinical trials, the most commonly occurring adverse reactions included neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit www.mgipharma.com or www.dacogen.com for full prescribing information.

About Gliadel(R) Wafer

Gliadel is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel is also indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. As a Gliadel Wafer dissolves, BCNU is delivered directly to the site once occupied by the tumor. Side effects that have been reported in patients receiving Gliadel include seizures, intracranial infections, abnormal wound healing, and brain edema (swelling). Although these events may result as a consequence of brain surgery (craniotomy) without Gliade
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:7/23/2008)...CISCO, July 23 /- InCode BioPharmaceu... today announced preclinical test,results demonstr...-1 for,the treatment of the rare chronic blood dis...he complete results will be presented at the XXII,...rland, September 28,2008., The only treatment cu...
(Date:7/22/2008)..., Australia, July 22 /- Fol...rday, the Board of Progen,Pharmaceuticals Limited ...ad discontinued the PI-88 phase 3 study in liver c... develop its existing portfolio of compounds and,t...l compounds and,opportunities through Merger & Acq...
(Date:7/22/2008)...wards under Therapeutics Development Initiative br...to 23; next deadline January 20,2009, NEW YORK, ...mission to,speed delivery of transformative treatm...el J. Fox Foundation for Parkinson,s Research has ...try research teams. The awards,were granted under ...
(Date:7/22/2008)...the-Art PET Study Confirms Tyrima Exhibits Excelle...es - - Results Support Initiation of Phase I..., July 22 /- CeNeRx BioPharma,Inc., ...izing innovative,treatments for diseases of the ce...ance its lead candidate Tyrima(TM) into Phase II t...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Quality of Life an Issue in Prostate Cancer Treatment 14764 1Quality of Life an Issue in Prostate Cancer Treatment 14764 2Quality of Life an Issue in Prostate Cancer Treatment 14764 3HHS Secretary Leavitt Praised for Defending Physicians Conscience Rights 14759 1HHS Secretary Leavitt Praised for Defending Physicians Conscience Rights 14759 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 1Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 3Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 4American Idol Spotlights Malaria Crisis During Idol Gives Back April 9 On FOX 14753 1American Idol Spotlights Malaria Crisis During Idol Gives Back April 9 On FOX 14753 2
...-USNewswire/ -- The,following statement may be att...he Advancement of Medical Research (CAMR): , "In t...Bush once,again used the stroke of his veto pen de...d medical research, as well as endanger,the future...,executive order directing NIH to continue pursuin...
...e 2 Diabetes Presented at the,67th Annual Scientif...FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, I...cused on the development,of therapeutics to treat ...on of top line data of its phase 2a study of DIO-9...or for the treatment of,type 2 diabetes. , Results...
Other Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 3
(Date:7/25/2008)...CESS, N.Y., July 25 /PRNewswire-USNewswire/ -- Ant...f Quality Officer and Vice President,of Strategic ...th Fund, a,national foundation committed to improv...ted the foundation,s Program on Health Care Qualit....newscom.com/cgi-bin/prnh/20080725/DC28791LOGO ),...
(Date:7/25/2008)...ON, Calif., July 25 /PRNewswire-FirstCall/ -- Thor...n device-based mechanical,circulatory support ther...,today announced that it will report its operating...hs of fiscal 2008 on Thursday, July 31., The comp...ancial,results and operating activities to all int...
(Date:7/25/2008)...A July 24, 2008 Being overweight or obese is not...ut is also a public health issue that impacts othe...ealth Services Research reveals that the extra Me...ple could place a significant financial burden on ...dollars across the entire current Medicare populat...
(Date:7/25/2008)...July 25 /PRNewswire/ -- BeaconEquity.com announces... news today., Investors can view all of the daily...nEquity.com/m , Today,s Trade Alerts include: DUS...ok Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMed ..., Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis Inc....
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
...cern over the AIDS crisis ravaging sub-Saharan Afr...'s XIII International AIDS Conference, researchers...many consider to be the next big trouble spot--Ind...ffing, and if there's an enemy of India it's not P...
... high levels of cholesterol but low levels that ar... Low levels of Cholesterol maybe linked to depress...en with relatively low cholesterol levels were up ... severe depression. Edward Suarez, PhD from Duke ...
...uld get a second medical opinion if they are told ...id tumors that could become cancerous.//'It is ver...cerous,' said Dr. Nelson Teng, chief of gynecologi...ool of Medicine.Fibroids are benign growths in the...
... all of you who thought that one only uses cortico...that have come out in the recent years which are d...Using Tacrolimus, the agent which was devised for ...st symptomatic relief of patients. Eczema is a dev...
Other Medicine News:
Every so often a new product comes along that isn't a small step but a giant leap ahead of everything that has preceeded it. Such is the impact of the Fidelity IAB.
...the perfect partner for growing your business prac...e scalable to meet your needs now and in the years...r FD20 system supports mixed-use as well as dedica...ws you to add new applications and techniques such...
...on CFX series represents a breakthrough that makes...ty. Its revolutionary design integrates Quantum 64...ies and advanced software. In fact, Aquilion CFX ... shown a sensitivity of 88% and specificity of 91%...
...2000 represents a new non-invasive approach to the...stem rapidly induces mild hypothermia in those pat...ia or rapidly reduces temperature in febrile patie...aintains core body temperature in a range of 33C (...
Medicine Products: